SK285461B6 - Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid - Google Patents

Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid Download PDF

Info

Publication number
SK285461B6
SK285461B6 SK1609-98A SK160998A SK285461B6 SK 285461 B6 SK285461 B6 SK 285461B6 SK 160998 A SK160998 A SK 160998A SK 285461 B6 SK285461 B6 SK 285461B6
Authority
SK
Slovakia
Prior art keywords
kim
seq
thr
protein
antibody
Prior art date
Application number
SK1609-98A
Other languages
English (en)
Slovak (sk)
Other versions
SK160998A3 (en
Inventor
Michele Sanicola-Nadel
Joseph V. Bonventre
Catherine A. Hession
Takaharu Ichimura
Henry Wei
Richard L. Cate
Original Assignee
Biogen Idec Ma Inc.
The General Hospital Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26690881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285461(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Ma Inc., The General Hospital Corporation filed Critical Biogen Idec Ma Inc.
Publication of SK160998A3 publication Critical patent/SK160998A3/sk
Publication of SK285461B6 publication Critical patent/SK285461B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
SK1609-98A 1996-05-24 1997-05-23 Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid SK285461B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1822896P 1996-05-24 1996-05-24
US2344296P 1996-08-23 1996-08-23
PCT/US1997/009303 WO1997044460A1 (en) 1996-05-24 1997-05-23 Modulators of tissue regeneration

Publications (2)

Publication Number Publication Date
SK160998A3 SK160998A3 (en) 1999-07-12
SK285461B6 true SK285461B6 (sk) 2007-02-01

Family

ID=26690881

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1609-98A SK285461B6 (sk) 1996-05-24 1997-05-23 Izolovaný polypeptid KIM, modulátor tkanivovej regenerácie a nukleová kyselina, ktorá ho kóduje, spôsob prípravy polypeptidu a farmaceutická kompozícia obsahujúca polypeptid

Country Status (26)

Country Link
US (4) US6664385B1 (de)
EP (2) EP0907735B9 (de)
JP (3) JP4602482B2 (de)
CN (1) CN1147584C (de)
AT (1) ATE318903T1 (de)
AU (1) AU712289B2 (de)
BG (1) BG64678B1 (de)
BR (1) BR9709115A (de)
CA (1) CA2257851C (de)
CZ (1) CZ295936B6 (de)
DE (1) DE69735364T3 (de)
DK (1) DK0907735T5 (de)
EA (1) EA004402B1 (de)
EE (1) EE04817B1 (de)
ES (1) ES2258793T5 (de)
HU (1) HU226205B1 (de)
IL (1) IL127162A (de)
IS (1) IS2636B (de)
NO (2) NO327597B1 (de)
NZ (1) NZ336467A (de)
PL (1) PL188826B1 (de)
PT (1) PT907735E (de)
SI (1) SI0907735T2 (de)
SK (1) SK285461B6 (de)
TR (1) TR199802421T2 (de)
WO (1) WO1997044460A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04817B1 (et) * 1996-05-24 2007-04-16 Biogen, Incorporated Kudede regeneratsiooni modulaatorid
JP2002516572A (ja) * 1997-05-23 2002-06-04 バイオジェン，インコーポレイテッド 組織の再生の調節
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1160321A1 (de) * 2000-05-31 2001-12-05 Sanofi-Synthelabo Kidney Injury Novel Gene-1: Isolierung und therapeutische Verwendungen
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
US6812002B2 (en) 2000-08-30 2004-11-02 Pfizer Inc. Osteoactivin protein and nucleic acids encoding the same, compositions and methods of stimulating bone differentiation
DK1401869T3 (da) 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
JP4572276B2 (ja) 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
SI1585546T1 (sl) 2002-12-30 2008-12-31 Biogen Idec Inc KIM-1 antagonisti in uporaba za moduliranje imunskega sistema
US8067544B2 (en) 2003-03-19 2011-11-29 Curagen Corporation Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
DK2360475T3 (da) * 2003-03-27 2020-01-06 Childrens Hospital Med Ct Fremgangsmåde og kit til detektion af tidlig indtræden af renal tubulær celleskade
EP1750500B1 (de) 2004-05-06 2015-07-08 The Trustees of Columbia University in the City of New York Ngal zur verringerung und verbesserung von ischämischen und nephrotoxischen schäden
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
RU2283666C9 (ru) * 2004-05-14 2007-03-10 Бизяев Алексей Вячеславович Средство для активации восстановления структуры и функции поврежденных тканей и органов
US20060003345A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc RNA bioassay
NZ555926A (en) * 2004-12-20 2008-11-28 Antibodyshop As Determination of neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic marker for renal disorders
BRPI0608254A2 (pt) 2005-03-02 2009-12-08 Biogen Idec Inc anticorpos kim-1 para o tratamento de condições mediadas por th2
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
AU2006315580A1 (en) 2005-11-10 2007-05-24 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen
EP2035835B1 (de) 2006-05-30 2011-12-28 Antibodyshop A/S Verfahren zur schnellen beurteilung der schwere eines traumas
EP2602624A1 (de) * 2006-08-07 2013-06-12 Antibodyshop A/S Diagnostischer Test zum Ausschliessen einer signifikanten Nierenverletzung
CN101680903A (zh) * 2007-03-21 2010-03-24 比奥波托诊断股份公司 肾损伤的诊断试验
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090297479A1 (en) * 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
BRPI0917711A2 (pt) * 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
WO2010025434A1 (en) * 2008-08-29 2010-03-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN106370857A (zh) 2008-10-21 2017-02-01 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN104076152B (zh) * 2008-10-21 2017-04-19 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
JP5752600B2 (ja) 2008-11-10 2015-07-22 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
CN103439510B (zh) * 2008-11-22 2016-09-14 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN102300875B (zh) * 2009-01-28 2014-07-16 财团法人工业技术研究院 肾病相关的生物标记
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US8871459B2 (en) 2009-08-07 2014-10-28 Astute Medical, Inc. Method for evaluating renal status by determining beta-2-glycoprotein 1
EP2462446B1 (de) * 2009-08-07 2017-09-27 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
NZ599773A (en) 2009-11-07 2014-09-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102725636B (zh) 2009-12-20 2015-04-01 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
CA2788826C (en) 2010-02-05 2023-09-26 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2539712A4 (de) 2010-02-26 2013-09-18 Astute Medical Inc Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
PL2672980T3 (pl) * 2011-02-09 2018-05-30 Lavivo Ab Synbiotyczne kompozycje dla odnowienia i odtworzenia flory bakteryjnej jelita
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2925337B1 (de) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutante ngal-proteine und verwendungen davon
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US10420337B2 (en) 2013-03-15 2019-09-24 Lifeline Scientific, Inc. Transporter with a glucose sensor for determining viability of an organ or tissue
WO2015134671A1 (en) 2014-03-04 2015-09-11 Targeson, Inc. Molecular imaging contrast agents and uses thereof
CN109844526A (zh) 2016-06-06 2019-06-04 机敏医药股份有限公司 使用胰岛素样生长因子结合蛋白7和金属蛋白酶2的组织抑制剂管理急性肾损伤

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
CA2118508A1 (en) * 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
WO1995021922A2 (en) * 1994-02-14 1995-08-17 Abbott Laboratories Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
US5622861A (en) * 1994-08-05 1997-04-22 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA encoding hepatitis A virus receptor
CA2196892A1 (en) * 1994-08-18 1996-02-29 The Trustees Of Columbia University Unique associated kaposi's sarcoma virus sequences and uses thereof
US6069230A (en) * 1994-11-10 2000-05-30 Promega Corporation High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
EE04817B1 (et) * 1996-05-24 2007-04-16 Biogen, Incorporated Kudede regeneratsiooni modulaatorid
DE60137934D1 (de) * 2000-06-16 2009-04-23 Biogen Idec Inc Renale regulatorische elemente und deren verwendung
DK1401869T3 (da) * 2001-06-01 2008-04-28 Biogen Idec Inc Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1
US7838220B2 (en) * 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
JP4572276B2 (ja) * 2001-06-29 2010-11-04 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニヴァーシティ Ｔ細胞調節遺伝子およびその使用方法
US7215871B2 (en) * 2001-07-27 2007-05-08 Thomson Licensing Changing a playback speed for video presentation recorded in a field structure format
US7687454B2 (en) * 2001-12-03 2010-03-30 The University Of British Columbia Effectors of innate immunity determination
JP4694128B2 (ja) * 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
AU2003228336B2 (en) * 2002-03-19 2009-07-30 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
SI1585546T1 (sl) * 2002-12-30 2008-12-31 Biogen Idec Inc KIM-1 antagonisti in uporaba za moduliranje imunskega sistema
TW200539890A (en) * 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
WO2005097211A2 (en) * 2004-03-24 2005-10-20 Telos Pharmaceuticals, Inc. Compositions as adjuvants to improve immune responses to vaccines and methods of use

Also Published As

Publication number Publication date
EA199801044A1 (ru) 1999-04-29
IS4902A (is) 1998-11-20
DE69735364D1 (de) 2006-04-27
PL330313A1 (en) 1999-05-10
BR9709115A (pt) 1999-08-03
CN1223685A (zh) 1999-07-21
JP4316640B2 (ja) 2009-08-19
WO1997044460A1 (en) 1997-11-27
IS2636B (is) 2010-06-15
HU226205B1 (en) 2008-06-30
HUP9902770A3 (en) 2001-09-28
JP2001505761A (ja) 2001-05-08
EE04817B1 (et) 2007-04-16
HUP9902770A2 (hu) 1999-12-28
NO985427D0 (no) 1998-11-20
JP2008067701A (ja) 2008-03-27
CZ295936B6 (cs) 2005-12-14
CA2257851A1 (en) 1997-11-27
HK1021746A1 (en) 2000-06-30
DK0907735T4 (da) 2009-12-21
NO985427L (no) 1999-01-25
NZ336467A (en) 2000-10-27
CA2257851C (en) 2011-11-15
ATE318903T1 (de) 2006-03-15
US20050089868A1 (en) 2005-04-28
NO20090945L (no) 1999-01-25
BG102967A (bg) 2000-05-31
SI0907735T1 (sl) 2006-08-31
ES2258793T5 (es) 2010-01-25
DK0907735T5 (da) 2010-06-14
CZ381398A3 (cs) 1999-05-12
EP0907735B9 (de) 2010-05-19
NO327597B1 (no) 2009-08-31
EE9800409A (et) 1999-06-15
JP2009039111A (ja) 2009-02-26
EP1655367A1 (de) 2006-05-10
SI0907735T2 (sl) 2010-01-29
IL127162A0 (en) 1999-09-22
EP0907735B2 (de) 2009-10-07
DK0907735T3 (da) 2006-06-26
US20060286031A1 (en) 2006-12-21
PL188826B1 (pl) 2005-04-29
TR199802421T2 (xx) 1999-02-22
SK160998A3 (en) 1999-07-12
AU3567697A (en) 1997-12-09
CN1147584C (zh) 2004-04-28
EP0907735A1 (de) 1999-04-14
PT907735E (pt) 2006-06-30
US20070141590A1 (en) 2007-06-21
JP4602482B2 (ja) 2010-12-22
BG64678B1 (bg) 2005-11-30
AU712289B2 (en) 1999-11-04
EA004402B1 (ru) 2004-04-29
US6664385B1 (en) 2003-12-16
ES2258793T3 (es) 2006-09-01
DE69735364T2 (de) 2006-11-30
EP0907735B1 (de) 2006-03-01
IL127162A (en) 2007-07-24
DE69735364T3 (de) 2010-05-06

Similar Documents

Publication Publication Date Title
AU712289B2 (en) Modulators of tissue regeneration
EP0914339B1 (de) RET-LIGAND 3 (RetL3), UM NEURALES UND RENALES WACHSTUM ZU STIMULIEREN
US6861509B1 (en) Antibodies to Ret and RetL3
WO2001016169A2 (en) RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE
KR100498530B1 (ko) 조직재생조절물질
KR100554901B1 (ko) 신경및신장증식을자극하기위한RET리간드(RetL)
MXPA98009812A (en) Modulators of the regeneration of the tej
HK1021821A1 (en) Ret ligand 3 (retl3) for stimulating neural and renal growth
HK1021821B (en) Ret ligand 3 (retl3) for stimulating neural and renal growth
HK1101184A (en) Ret ligand (retl) for stimulating neural and renal growth

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20170523